Published in final edited form as:

Amino Acids. 2011 May ; 40(5): 1503–1511. doi:10.1007/s00726-010-0760-7.

New potent biphalin analogues containing *p*-fluoro-L-phenylalanine at the 4,4' positions and non-hydrazine linkers

Adriano Mollica,

Dipartimento di Scienze del Farmaco, Università di Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Italy

Francesco Pinnen,

Dipartimento di Scienze del Farmaco, Università di Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Italy

Federica Feliciani,

Dipartimento di Scienze del Farmaco, Università di Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Italy

Azzurra Stefanucci,

Dipartimento di Scienze del Farmaco, Università di Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, 66100 Chieti, Italy

Gino Lucente,

Istituto di Chimica Biomolecolare (CNR) c/o Dipartimento di Chimica e Tecnologie del Farmaco, "Sapienza", Università di Roma, P.le A.Moro, 00185 Rome, Italy

Peg Davis,

Department of Pharmacology, University of Arizona, Tucson, AZ 85719, USA

Frank Porreca,

Department of Pharmacology, University of Arizona, Tucson, AZ 85719, USA

Shou-Wu Ma,

Department of Pharmacology, University of Arizona, Tucson, AZ 85719, USA

Josephine Lai, and

Department of Pharmacology, University of Arizona, Tucson, AZ 85719, USA

Victor J. Hruby

Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, USA

Abstract

We report the synthesis and the biological evaluation of two new analogues of the potent dimeric opioid peptide biphalin. The performed modification is based on the replacement of two key structural elements of the native biphalin, namely: the hydrazine bridge which joins the two palindromic moieties and the phenylalanine residues at the 4,4' positions of the backbone. The

Correspondence to: Adriano Mollica.

Conflict of interest The authors declare that they have no conflict of interest.

new analogues **9** and **10** contain 1,2-phenylenediamine and piperazine, respectively, in place of the hydrazidic linker and *p*-fluoro-L-phenylalanine residues at 4 and 4' positions. Binding values are: $K_i^\mu=0.51$ nM and $K_i^\delta=12.8$ nM for compound **9**, $K_i^\mu=0.09$ nM and $K_i^\delta=0.11$ nM for analogue **10**.

Keywords

Activity; Biphalin; Dimeric peptide ligands; Opioid peptides; Synthesis

Introduction

The opioid pentapeptide enkephalins (Tyr-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu) were originally isolated from pig and cow brain (Hughes et al. 1975). Enkephalins are endogenous δ ligands of the opioid multiple receptor family located in neuronal cell membranes which express the extensively studied μ -, δ - and κ -opioid receptors. As expected for simple linear oligopeptides, enkephalins are highly sensitive to enzymatic degradation and, in addition to this, exhibit low receptor binding selectivity and minimal capacity to cross the phospholipid bilayer (Hruby and Gehrig 1989). Generally unfit as therapeutic agents, native enkephalins continue to represent the reference structural model for studies on recognition and binding mechanisms of peptide ligands as well as for the development of secondary effect-free analgesics to be used in place of morphine.

Based on extensive SAR studies, a variety of synthetic strategies has been adopted to modify the enkephalin native structure and most of the relevant opioid peptide ligands so far described are enkephalin-based. Among consolidated findings in this field is the role exerted on enkephalin activity by the phenylalanine residue in position 4. It has been shown that the aromatic residue at position 4 can significantly modulate binding to the μ - and δ -opioid receptors (Morgan et al. 1976; Chang et al. 1976; Schiller et al. 1978). Modification of this residue, by introducing substituents at the *para* position of the aromatic ring, significantly enhances the activity with the highest effect shown by the introduction of electron-drawing groups (Schiller et al. 1983). Moreover, it has been found that the positive consequences of the modification performed at the Phe⁴ aromatic ring of enkephalins are maintained in the case of the highly active synthetic octapeptide biphalin (Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Gly-D-Ala-Tyr; Fig. 1; Abbruscato et al. 1996; Li et al. 1998; Misicka et al. 1999).

Biphalin represents one of the most successful applications of the dimeric ligand approach to the design of native bioactive peptide analogues (Coy et al. 1976; Lipkowski et al. 1982; Shimohigashi et al. 1982; Horan et al. 1993). Its structure is characterized by two enkephalin-derived bio-active fragments joined "tail to tail" by a hydrazide bridge. The presence of two pharmacophores, combined with an appropriate linker, confers on biphalin highly affinity for both δ - and μ -receptors, a potency significantly higher than morphine after i.c.v. and i.t. administration (Lipkowski et al. 1987; Horan et al. 1993) and less physical dependence than morphine (Horan et al. 1993; Yamazaki et al. 2001). Consequently, biphalin continues to be the object of chemical modifications and structural studies aimed at further improving the activity as well as to better understand the molecular bases of its interaction with opioid receptors.

Modification of the 4,4' residues of biphalin, by symmetrical incorporation of *para*-fluoro or *para*-nitro phenylalanine residues (see Fig. 1), leads to analogues which show, although to different degrees, enhancement of affinity towards δ - and μ -opioid receptors accompanied by an increase of δ/μ selectivity (Misicka et al. 1997; Li et al. 1998). Recently, Hruby and co-workers reported on a series of biphalin analogues in which the –NH–NH– linker is replaced by different non-hydrazidic bridges, namely the residues of 1,4-phenylenediamine, 1,2-phenylenediamine and piperazine (see Fig. 1, compounds **9a** and **10a**) (Mollica et al. 2005). These new analogues show better affinity and in vitro bioactivity than biphalin itself, thus suggesting that the high activity of biphalin is not critically related to the structural and conformational properties of the hydrazide bridge nor to its capability to form hydrogen bonds with the opioid receptors.

With the aim to investigate the effects of the *para* substitution at the Phe⁴ aromatic ring combined with hydrazine bridge replacements, we report here synthesis and in vitro assays of two new fluorinated biphalin analogues **9** and **10** containing non-hydrazine linkers.

Chemistry

In the present study, the previously adopted strategy for the synthesis of non-hydrazine biphalin analogues has been modified. As illustrated in Scheme 1, the amino acid residues were symmetrically added one by one to the linkers. This procedure allows an easier isolation and characterization of the intermediate products and avoids possible racemization connected with alkaline hydrolysis of the intermediate tripeptide ester Boc-Tyr-D-Ala-Gly-OEt.

General procedures

All products were synthesized in solution using the EDC/HOBt/DIPEA coupling method (Scheme 1). The N^α terminal Boc-protected peptides were all deprotected by a mixture of TFA in DCM 1:1 at r.t. The intermediate TFA salts were used for subsequent reactions without further purification. Intermediate products **3** and **5** were purified by precipitation in EtOAc, the filtrate was washed on a Buchner funnel with 3× 50 mL of NaHCO₃ s.s., 3× 50 mL of 5% citric acid, 3× 50 mL of deionized water, dried under vacuum, followed by trituration with diethyl ether and used in the next step without further purification. Products **1**, **2**, **4** and **6** were purified by silica gel column chromatography. Final products **7**, **8**, **9** and **10** were purified by RP-HPLC using a Waters XBridge™ Prep BEH130 C₁₈, 5.0 μm, 250 mm × 10 mm column, HPLC solvent A, 0.1% TFA in water; solvent B, acetonitrile; gradient: 5–95% B in A over 45 min, flow rate 5.0 mL/min.

The purity of the N^α-Boc-protected products and the final TFA salts was assessed by analytical RP-HPLC, TLC confirmed by NMR analysis and mass spectrometry ESI-HRMS (see Table 1).

(Boc-pF-Phe)₂-piperazine (1)—EDC·HCl (2.2 eq.), HOBt (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-pF-Phe-OH (2.2 eq.) in DMF at 0°C. The reaction mixture was stirred for 10 min, piperazine (1 eq.) was added and the reaction was stirred for an additional 10 min at 0°C and then allowed to warm at r.t. overnight. The solvent was

evaporated under reduced pressure, the residue was precipitated with EtOAc and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water. The solid was dried under reduced pressure and triturated with diethyl ether to give the desired product **1** as a crude white solid. $R_f^I=0.27$ (CH₂Cl₂/AcOEt 8:2), $R_f^{II}=0.71$ (CH₂Cl₂/AcOEt 1:1). The product was purified by silica gel column chromatography (CH₂Cl₂/AcOEt 8:2 to CH₂Cl₂/EtOAc 3:7) to obtain the pure product **1** (92%). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ , ppm): 1.32 [9H, s, (CH₃)₃-]; 2.78–2.70 [4H, m, Phe β -CH₂]; 3.41–3.26 [8H, m, -CH₂-CH₂-]; 4.55 [2H, m, Phe α -CH]; 7.30–7.07 [8H, m, aromatics]; 7.25 [2H, d, Phe NH]. ¹³C NMR (CDCl₃, 300 MHz) (δ , ppm): 28.5, 39.6, 41.6, 45.2, 51.1, 80.3, 115.8, 131.2, 132.1, 155.2, 160.5, 170.3. HRMS (ESI) calcd. for C₃₂H₄₃F₂N₄O₆ *m/z*: 617.3151 [M + H]⁺; found 617.3155.

(Boc-pF-Phe)₂-1,2-phenylenediamine (2)—EDC·HCl (2.2 eq.), HOBt (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-pF-Phe-OH (2.2 eq.) in DMF at 0°C. The reaction mixture was stirred for 10 min, 1,2-phenylenediamine (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C and then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc, and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water. Then the solid was dried under reduced pressure and triturated with diethyl ether to give the desired product **2** as a crude white solid. $R_f^I=0.40$ (CH₂Cl₂/AcOEt 8:2), $R_f^{II}=0.33$ (CHCl₃/CH₃OH 98:2). The product was purified by silica gel column chromatography (CH₂Cl₂/AcOEt 95:5 to CH₂Cl₂/AcOEt 7:3) to obtain the pure product **2** (41%). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ , ppm): 1.31 [9H, s, (CH₃)₃-]; 2.97–2.76 [4H, m, Phe β -CH₂]; 4.24 [2H, m, Phe α -CH]; 7.40–6.50 [12H, m, aromatics]; 6.95 [2H, d, Phe NH]; 9.46 and 9.23 [2H, two singlets, Ar NH]. ¹³C NMR (CDCl₃, 300 MHz) (δ , ppm): 28.5, 37.4, 56.5, 80.8, 115.8, 126.8, 130.3, 131.1, 132.4, 155.8, 160.5, 170.7. HRMS (ESI) calcd. for C₃₄H₄₁F₂N₄O₆ *m/z*: 639.2994 [M + H]⁺; found 639.2991.

(Boc-Gly-pF-Phe)₂-piperazine (3)—Product **1** was deprotected at the N ^{α} terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was used for the next step without further purification. EDC·HCl (2.2 eq.), HOBt (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-Gly-OH (2.2 eq.) in DMF at 0°C. The reaction mixture was stirred for 10 min, TFA-pF-Phe-Pip-pF-Phe·TFA (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water. The solid was dried under reduced pressure and triturated with diethyl ether to yield the desired product **3** as pure white solid (82%). $R_f^I=0.52$ (AcOEt), $R_f^{II}=0.61$ (AcOEt/CH₃OH 99:1). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ , ppm): 1.35 [9H, s, (CH₃)₃-]; 2.96–2.75 [4H, m, Phe β -CH₂]; 3.41–3.26 [8H, m, -CH₂-CH₂-]; 3.49 [4H, m, Gly CH₂]; 4.89 [2H, m, Phe α -

CH]; 6.65 [2H br, Gly *NH*]; 7.22–6.98 [8H, m, aromatics]; 7.90 [2H, d, Phe *NH*]. ¹³C NMR (CDCl₃, 300 MHz) (δ, ppm): 28.5, 38.7, 41.7, 45.2, 49.8, 60.6, 80.6, 115.9, 131.2, 131.7, 156.1, 160.5, 169.7, 171.4. HRMS (ESI) calcd. for C₃₆H₄₆F₂N₆O₈ *m/z*: 731.3580 [M + H]⁺; found 731.3588.

(Boc-Gly-pF-Phe)₂-1,2-phenylenediamine (4)—Product **2** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of the Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was used for the next step without further purification. EDC·HCl (2.2 eq.), HOBt (2.2 eq.), DIPEA (6.6 eq.) were added to a solution of Boc-Gly-OH (2.2 eq.) in DMF at 0°C and reaction mixture was stirred for 10 min, TFA·pF-Phe-1,2-phenylenediamine·pF-Phe·TFA (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc, and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water, then the solid dried under reduced pressure and triturated with diethyl ether to give the desired product **4** as a crude white solid. The product was purified by silica gel column chromatography (AcOEt/CH₂Cl₂ 1:1 to AcOEt/CH₂Cl₂ 8:2) to obtain the pure product **4** (77%). *R*_f^I=0.21 (AcOEt/CH₂Cl₂ 1:1), *R*_f^{II}=0.80 (AcOEt). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 3.22–2.86 [4H, m, Phe β-CH₂]; 3.55 [4H, m, Gly *NH*]; 4.77 [2H, m, Phe α-CH]; 7.22–6.59 [12H, m, aromatics]; 7.99 [4H, br, Gly *NH*]; 8.88 [2H, br, Phe *NH*]; 9.70 [2H, s, Ar *NH*]. ¹³C NMR (CDCl₃, 300 MHz) (δ, ppm): 28.4, 37.1, 55.3, 60.6, 80.7, 115.9, 125.5, 126.8, 131.1, 132.1, 132.2, 156.7, 160.5, 170.2, 170.6. HRMS (ESI) calcd. for C₃₈H₄₇F₂N₆O₃ *m/z*: 753.3426 [M + H]⁺; found 753.3425.

(Boc-D-Ala-Gly-pF-Phe)₂-piperazine (5)—Product **3** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of the mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was used for the next step without further purification. EDC·HCl (2.2 eq.), HOBt (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-D-Ala-OH (2.2 eq.) in DMF at 0°C. The reaction mixture was stirred for 10 min, TFA·Gly-pF-Phe-Pip-pF-Phe-Gly·TFA (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water, then dried under reduced pressure and triturated with diethyl ether to give the desired product **5** as a pure white solid (60%). *R*_f^I=0.16 (AcOEt/CH₃OH 9:1), *R*_f^{II}=0.80 (AcOEt/CH₃OH 8:2). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 1.16 [6H, m, Ala CH₃]; 1.34 [9H, s, (CH₃)₃-]; 2.89–2.74 [4H, m, Phe β-CH₂]; 3.41–3.10 [8H, m, -CH₂-CH₂-]; 3.67–3.55 [4H, m, Gly CH₂]; 3.98 [2H, m, D-Ala α-CH]; 4.83 [2H, m, Phe α-CH]; 6.98 [2H, d, D-Ala *NH*]; 7.23–7.04 [8H, m, aromatics]; 7.96 [2H, t, Gly *NH*]; 8.21 [2H, d, Phe *NH*]. ¹³C NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 18.7, 28.8, 37.3,

42.1, 42.3, 50.2, 50.3, 78.7, 115.6, 131.9, 133.9, 155.7, 160.1, 168.8, 169.6, 173.6. HRMS (ESI) calcd. for $C_{42}H_{59}F_2N_8O_{10}$ m/z : 873.4322 $[M + H]^+$; found 873.4318.

(Boc-D-Ala-Gly-pF-Phe)₂-1,2-phenylenediamine (6)—Product **4** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was used for the next step without further purification. EDC·HCl (2.2 eq.), HOBT (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-D-Ala-OH (2.2 eq.) in DMF at 0°C and stirred for 10 min. TFA·Gly-pF-Phe-1,2-phenylenediamine-pF-Phe-Gly·TFA (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C, then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water, dried under reduced pressure and triturated with diethyl ether to give the desired product **6** as a crude white solid. $R_f^I=0.34$ (AcOEt), $R_f^{II}=0.50$ (AcOEt/CH₃OH 99:1). The product was purified by silica gel column chromatography (AcOEt/CH₂Cl₂ 1:1 to AcOEt/CH₂Cl₂ 94:6) to obtain the pure product **6** (35%). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 1.16 [6H, m, Ala CH₃]; 1.34 [9H, s, (CH₃)₃-]; 3.18–2.74 [4H, m, Phe β-CH₂]; 3.81–3.61 [4H, m, Gly CH₂]; 3.95 [2H, m, D-Ala α-CH]; 4.60 [2H, m, Phe α-CH]; 7.35–6.50 [12H, m, aromatics]; 7.50 [2H, br, D-Ala NH]; 8.05 [2H, t, Gly NH]; 8.21 [2H, d, Phe NH]; 9.50 [2H, s, Ar NH]. ¹³C NMR (CDCl₃, 300 MHz) (δ, ppm): 18.7, 28.5, 37.1, 43.1, 50.6, 55.9, 80.4, 115.7, 125.4, 126.6, 130.4, 131.1, 132.5, 156.0, 160.4, 169.9, 170.4, 174.3. HRMS (ESI) calcd. for $C_{44}H_{57}F_2N_8O_{10}$ m/z : 895.4166 $[M + H]^+$; found 895.4160.

(Boc-Tyr-D-Ala-Gly-pF-Phe)₂-piperazine (7)—Product **5** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was used for the next step without further purification. EDC·HCl (2.2 eq.), HOBT (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-Tyr-OH (2.2 eq.) in DMF at 0°C and stirred for 10 min. TFA·D-Ala-Gly-pF-Phe-Pip-pF-Phe-Gly-D-Ala·TFA (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc and the suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water, dried under reduced pressure and triturated with diethyl ether to give the product **7** as crude white solid. The product was purified on RP-HPLC to give the pure product **7** (90%). $R_f^I=0.20$ (AcOEt/MeOH 9:1), $R_f^{II}=0.73$ (CHCl₃/MeOH 8:2). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 1.15 [6H, m, Ala CH₃]; 1.32 [9H, s, (CH₃)₃-]; 2.98–2.54 [8H, m, Phe β-CH₂ and Tyr β-CH₂]; 3.45–3.10 [8H, m, -CH₂-CH₂- superimposed to the water signal]; 3.65 [4H, m, Gly CH₂]; 4.05 [2H, m, D-Ala αCH]; 4.22 [2H, m, Tyr α-CH]; 4.85 [2H, m, Phe α-CH]; 6.90 [2H, d, Tyr NH]; 7.25–6.64 [16H, m, aromatics]; 8.05 [4H, br, Phe NH and D-Ala]; 8.22 [2H, t, Gly NH]; 9.20 [2H, s, Tyr OH]. ¹³C NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 18.7, 28.8, 37.4, 38.4, 45.2, 48.8, 50.1, 56.7, 60.4, 78.8,

115.4, 128.5, 128.9, 130.0, 130.8, 137.8, 155.9, 156.4, 168.6, 169.8, 172.0, 173.0. HRMS (ESI) calcd. for $C_{60}H_{77}F_2N_{10}O_{14}$ m/z : 1,199.5589 $[M + H]^+$; found 1,199.5586.

(Boc-Tyr-D-Ala-Gly-pF-Phe)₂-1,2-phenylenediamine (8)—Product **6** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was used for the next step without further purification. EDC·HCl (2.2 eq.), HOBt (2.2 eq.) and DIPEA (6.6 eq.) were added to a solution of Boc-Tyr-OH (2.2 eq.) in DMF at 0°C. The reaction mixture was stirred for 10 min. TFA·D-Ala-Gly-pF-Phe-1,2-phenylenediamine-pF-Phe-Gly-D-Ala·TFA (1 eq.) was added, the reaction was stirred for an additional 10 min at 0°C, then allowed to warm at r.t. overnight. The solvent was evaporated under reduced pressure, the residue was precipitated with EtOAc and suspension was filtered through a Buchner funnel under reduced pressure. The solid residue was washed with three portions of 5% citric acid, NaHCO₃ s.s., brine and distilled water, dried under reduced pressure and triturated with diethyl ether to give the desired product **8** as a crude white solid.

$R_f^I=0.46$ (AcOEt/MeOH 9:1), $R_f^{II}=0.37$ (CHCl₃/MeOH 9:1). The product was purified on RP-HPLC to give the pure product **8** (30%). ¹H NMR (DMSO-*d*₆, 300 MHz) (δ , ppm): 1.16 [6H, m, Ala CH₃]; 1.32 [9H, s, (CH₃)₃-]; 3.15–2.42 [8H, m, Tyr β -CH₂ and Phe β -CH₂]; 3.70 [4H, m, Gly CH₂]; 4.03 [2H, m, D-Ala α -CH]; 4.23 [2H, m, Tyr α -CH]; 4.65 [2H, m, Phe α -CH]; 7.42–6.59 [20H, m, aromatics]; 6.85 [2H, d, Tyr NH]; 8.22–8.05 [6H, br, D-Ala NH, Gly NH and Phe NH]; 9.50 and 9.15 [4H, two singlets, Tyr OH and Ar NH]. ¹³C NMR (DMSO-*d*₆, 300 MHz) (δ , ppm): 18.7, 28.7, 37.1, 37.2, 42.5, 48.7, 56.8, 56.9, 78.8, 115.4, 115.6, 120.7, 128.5, 130.7, 130.8, 131.8, 133.3, 134.3, 156.0, 156.4, 160.1, 169.6, 170.6, 172.2, 173.1. HRMS (ESI) calcd. for $C_{62}H_{75}F_2N_{10}O_{14}$ m/z : 1,221.5432 $[M + H]^+$; found 1,221.5435.

2 TFA·(Tyr-D-Ala-Gly-pF-Phe)₂-1,2-phenylenediamine (9)—Product **8** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was purified on RP-HPLC to give the pure product **9** (78%). $R_f^I=0.69$ (*n*-Bu-OH/CH₃COOH/H₂O 4:1:1), $R_f^{II}=0.65$ (*n*-Bu-OH/CH₃COOH/AcOEt/H₂O 5:1:3:1). ¹H NMR (DMSO-*d*₆, 500 MHz) (δ , ppm): 1.05 [6H, m, Ala CH₃]; 3.20–2.90 [8H, m, Tyr β -CH₂ and Phe β -CH₂]; 3.60 [4H, m, Gly CH₂]; 4.00 [2H, m, Tyr α -CH]; 4.32 [2H, m, D-Ala α -CH]; 4.65 [2H, m, Phe α -CH]; 7.50–6.70 [20H, m, aromatics]; 8.06 [2H, br, Tyr NH]; 8.15 [4H, br, Gly NH and Phe NH]; 8.55 [2H, br, D-Ala NH]; 9.56 and 9.35 [4H, two singlets, Tyr OH and Ar NH]. ¹³C NMR (DMSO-*d*₆, 300 MHz) (δ , ppm): 18.9, 36.9, 37.2, 48.8, 54.2, 55.4, 55.5, 115.9, 125.4, 126.0, 131.1, 131.8, 134.3, 157.2, 158.6, 159.0, 160.1, 163.3, 168.3, 169.5, 170.7, 172.5. HRMS (ESI) calcd. for $C_{52}H_{59}F_2N_{10}O_{10}$ m/z : 1,021.4384 $[M + H]^+$; found 1,021.4381.

2 TFA·(Tyr-D-Ala-Gly-pF-Phe)₂-piperazine (10)—Product **7** was deprotected at the N^α terminal by TFA in DCM 1:1 using 1 mL of mixture per 100 mg of Boc-protected product for 1.5 h at r.t. The mixture was then evaporated under high vacuum and the TFA salt was purified on RP-HPLC to give the pure product **10** (90%). $R_f^I=0.46$ (*n*-Bu-OH/

CH₃COOH/H₂O 4:1:1), $R_f^{\text{II}}=0.12$ (*n*-Bu-OH/CH₃COOH/AcOEt/H₂O 5:1:3:1). ¹H NMR (DMSO-*d*₆, 500 MHz) (δ, ppm): 1.08 [6H, m, Ala CH₃]; 2.98–2.77 [8H, m, Tyr β-CH₂ and Phe β-CH₂]; 3.35 [8H, m, piperazine protons under the water signal]; 3.68 [4H, m, Gly CH₂]; 3.99 [2H, m, Tyr α-CH]; 4.35 [2H, m, D-Ala α-CH]; 4.90 [2H, m, Phe α-CH]; 7.25–6.67 [16H, m, aromatics]; 8.15 [2H, br, Tyr NH]; 8.25 [4H, br, Gly NH and Phe NH]; 8.58 [2H, br, D-Ala NH]; 9.34 [2H, s, Tyr OH]. ¹³C NMR (DMSO-*d*₆, 300 MHz) (δ, ppm): 18.9, 36.9, 42.1, 48.9, 50.2, 50.9, 54.2, 58.4, 115.6, 115.9, 125.4, 131.1, 132.0, 133.8, 157.2, 158.5, 158.9, 168.7, 169.9, 172.5, 172.6. HRMS (ESI) calcd. for C₅₀H₆₁F₂N₁₀O₁₀ *m/z*: 999.4540 [M + H]⁺; found 999.4542.

Biological assays

Receptor binding affinities to the δ- and μ-opioid receptors were performed using cell membrane preparations from transfected cells that stably express the respective receptor type and were evaluated as previously described (Polt et al. 1994; Misicka et al. 1992). The ligands used were [³H]DPDPE and [³H]DAMGO for δ- and μ-receptors, respectively.

We used [³⁵S]GTP-γ-*S* binding to examine opioid agonist efficacy and functional characterization of the ligands at the δ- and μ-opioid receptors. Agonist efficacy can be determined at the level of receptor G-protein interaction by measuring agonist-stimulated binding with a non-hydrolyzable GTP analogue. The ability of μ- and δ-opioid agonists to activate G-proteins has been demonstrated by studying the binding of the GTP analogue guanosine-5'-*O*-(3-[³⁵S]thio)triphosphate ([³⁵S]GTP-γ-*S*). The opioid receptor-mediated assay was performed as previously described (Szekeres and Traynor 1997). Cells expressing hDOR for δ-receptor (or rMOR for μ-receptor) were incubated with increasing concentrations of the test compounds in the presence of 0.1 nM [³⁵S]GTP-γ-*S* (1,000–1,500 Ci/mmol, MEN, Boston, MA) in assay buffer (total volume of 1 mL, duplicate samples) as a measure of agonist-mediated G-protein activation. After incubation (90 min, 30°C), the reaction was terminated by rapid filtration under vacuum through Whatman GF/B glass fibre filters, followed by four washes with ice-cold 15 mM Tris/120 mM NaCl, pH 7.4. Filters were pre-treated with assay buffer prior to filtration to reduce non-specific binding. Bound reactivity was measured by liquid scintillation spectrophotometry after an overnight extraction with EcoLite (ICN, Biomedicals, Costa Mesa, CA) scintillation cocktail. The data were analysed using GraphPad Prism Software (San Diego, CA).

The in vitro tissue bioassays (MVD and GPI/LMMP) were performed as described previously (Kramer et al. 1993). IC₅₀ values represent means of no less than four experiments. IC₅₀ values, relative potency estimates and their associated standard errors were determined by fitting the data to the Hill equation by a computerized non-linear least-squares method. All biological data are summarized in Table 2.

Results and discussion

In order to better discuss the consequences of the structural modifications, Table 2 reports, in addition to the activity data of the new analogues **9** and **10** and native biphalin, the biological evaluations previously found for pF-Bph, the pF-Phe analogue of biphalin (Misicka et al.

1997) and the analogues **9a** and **10a** (Mollica et al. 2005). The latter, as compared with **9** and **10**, maintain the non-hydrazine linker but lack the *para*-fluoro (pF) substitution at the 4,4'-Phe residues.

The positive influence of the introduction of a pF-Phe residue in position 4,4' of biphalin has already been reported and is analogous to that previously observed in the field of enkephalins (Toth et al. 1990). In particular, the pF-Phe containing biphalin analogue (see pF-Bph in Table 2), when compared to the parent, exhibits ten to two times higher affinity to δ - and μ -receptor types, respectively (Misicka et al. 1997).

Examination of the biological data reported in Table 2 confirms that, as already demonstrated (Mollica et al. 2005), the hydrazine bridge is not essential for binding and activity and that the pF substitution on the phenylalanine side chain maintains or improves the interaction of the ligands with both δ - and μ -opioid receptors.

When compared to biphalin, the fluorinated piperazinic derivative **10** shows improved binding values for both μ - and δ -receptors (0.11 vs. 1.4 nM and 0.09 vs. 2.6 nM, respectively). Furthermore, the GTP binding value (EC_{50} ; 1.0 nM) reveals an extremely high capacity to trigger the transduction mechanisms with an efficacy three to six times higher than biphalin for both receptors (0.8 vs. 2.5 and 1.0 vs. 6.0, for δ - and μ -receptors, respectively). In particular, the E_{max} exhibited by **10** (94.1%) is, to the best of our knowledge, the highest value so far reported for a noncyclic biphalin analogue. Table 2 shows that the new analogues **9** and **10** are both more active than biphalin: the IC_{50} (nM) of **10** is in fact 1:10 for μ /GPI receptors (2.7 vs. 27) and ca. 1:20 for δ /MVD (0.48 vs. 8.8). The corresponding values of **9** are ca. 1:30 for μ /GPI (0.7 vs. 27) and ca. 1:2 for δ /MVD (3.7 vs. 8.8).

It should be noted that, when compared with native biphalin, the activity data of the non-fluorinated analogues **9a** and **10a** (Fig. 1; Table 2) are in general comparable to those of corresponding analogues **9** and **10**. The non-fluorinated analogues, which share with **9** and **10** a non-hydrazine linker, show in fact greater binding affinities to both δ - and μ -receptors with respect to biphalin (Mollica et al. 2005). In analogue **10a**, which possesses a piperazine linker, the pF substitution improves all of the measured parameters and efficacy (see in vitro bioassays, binding assays, and GTP binding in Table 2). On the contrary, in the 1,2-phenylenediamine containing analogue **9a**, the pF substitution was detrimental for the δ binding assays (0.19 vs. 13) and three to four times better for μ binding assays (1.9 vs. 0.51). Concerning the GTP- γ - ^{35}S binding assays, the pF substitution leads to a 1.2–2-fold drop in efficacy for both receptors (E_{max} (%) is 83 and 89 for **9a** and 71.6 and 43.8 for **9**).

In summary, the reported results indicate that the improvement of the activity due to the replacement of the native hydrazine linker and those derived from the pF substitution on Phe aromatic ring at positions 4,4' are in part additive and synergistic, in particular for the stimulation of the second messenger system. As data in Table 2 show, the piperazine linker, as compared to the 1,2-phenylenediamine linker, confirms more favourable properties in bridging the two palindromic arms of biphalin. The absence in the piperazine moiety of the two CO–NH groups, available for H-bond donor interactions as well as its more flexible and

less planar structure, is probably at the basis of the different behaviours observed. The influence on the activity of the analogue **10** appears remarkable as the introduction of the piperazine link and the pF substitution leads to the most potent non-cyclic biphalin analogue so far described. This result can be only compared to that previously achieved with the synthesis of the cyclic biphalin analogue containing a disulphide Cys-Cys bridge (Mollica et al. 2006) which shows a $E_{\max}$ (%) value of 100. In the case of the opioid peptide **10** described here, the synthesis of a linear potent full agonist which escapes the problems and low yields often associated with the cyclization reactions may be a valuable advantage.

Acknowledgments

This study was supported in part by a grant from the USDHS, NIDA (DA06284).

Abbreviations

Boc	<i>tert</i> -Butyloxycarbonyl
[³H]DAMGQD-Ala(2), <i>N</i>-Me-Phe(4), Gly-ol(5)] enkephalin	
[³H]DPDPE	[³ H]-c[D-Pen ² , D-Pen ⁵]enkephalin
DCM	Dichloromethane
DIPEA	<i>N,N</i> -Diisopropylethylamine
DMAP	4-(Dimethylamino)pyridine
DMF	<i>N,N</i> -Dimethyl formamide
DMSO	Dimethylsulfoxide
EDC	1-Ethyl-(3-dimethylaminopropyl)carbodiimide
GPI/LMMP	Guinea pig ileum/longitudinal muscle myenteric plexus (μ -opioid receptors)
hMOR	Human μ -opioid receptor
HOBt	1-Hydroxybenzotriazole
MVD	Mouse vas deferens (δ -opioid receptors)
NMM	<i>N</i> -Methyl morpholine
rDOR	Rat δ -opioid receptor
TEA	Triethylamine
TFA	Trifluoroacetic acid

References

- Abbruscato TJ, Williams SA, Misicka A, Lipkowski AW, Hruby VJ, Davis TP. Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. *J Pharmacol Exp Ther.* 1996; 276:1049–1057. [PubMed: 8786534]

- Chang J-K, Fong BTW, Pert A, Pert CB. Opiate receptor affinities and behavioral effects of enkephalin: structure–activity relationship of ten synthetic peptide analogues. *Life Sci.* 1976; 18:1473–1481. [PubMed: 940427]
- Coy DH, Kastin AJ, Schally AV, Morin O, Caron NG, Labrie F, Walker JM, Fertel R, Berntson GG, Sandman CA. Synthesis and opioid activities of stereoisomers and other D-amino acid analogs of methionine-enkephalin. *Biochem Biophys Res Commun.* 1976; 73:632–638. [PubMed: 1008880]
- Horan PJ, Mattia A, Bilsky EJ, Weber S, Davis TP, Yamamura HI, Malatynska E, Appleyard SM, Slaninova J, Misicka A, Lipkowski AW, Hruby VJ, Porreca F. Antinociceptive profile of biphalin, a dimeric enkephalin analog. *J Pharmacol Exp Ther.* 1993; 265:1446–1454. [PubMed: 8389867]
- Hruby VJ, Gehrig CA. Recent developments in the design of receptor specific opioid peptides. *Med Res Rev.* 1989; 9:343–401. [PubMed: 2547125]
- Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. *Nature.* 1975; 258:577–579. [PubMed: 1207728]
- Kramer TH, Davis P, Hruby VJ, Burks TF, Porreca F. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. *J Pharmacol Exp Ther.* 1993; 266:577–584. [PubMed: 8394911]
- Li G, Haq W, Xiang L, Lou B-S, Hughes R, De Leon IA, Davis P, Gillespie TJ, Romanowski M, Zhu X, Misicka A, Lipkowski AW, Porreca F, Davis TP, Yamamura HI, O'Brien DF, Hruby VJ. Modifications of the 4,4'-residues and SAR studies of biphalin, a highly potent opioid receptor active peptide. *Bioorg Med Chem Lett.* 1998; 8:555–560. [PubMed: 9871617]
- Lipkowski AW, Konecka AM, Sroczynska I. Double-enkephalins—synthesis, activity on guinea-pig ileum, and analgesic effect. *Peptides.* 1982; 3:697–700. [PubMed: 7134034]
- Lipkowski AW, Konecka AM, Sroczynska I, Przewlocki R, Stala L, Tam SW. Bivalent opioid peptide analogues with reduced distances between pharmacophores. *Life Sci.* 1987; 40:2283–2288. [PubMed: 3035308]
- Lipkowski AW, Misicka A, Davis P, Stropova D, Janders J, Lachwa M, Porreca F, Yamamura HI, Hruby VJ. Biological activity of fragments and analogues of the potent dimeric opioid peptide, biphalin. *Bioorg Med Chem Lett.* 1999; 9:2763–2766. [PubMed: 10509931]
- Misicka A, Lipkowski AW, Horvath R, Davis P, Kramer TH, Yamamura HI, Hruby VJ. Topographical requirements for delta opioid ligands: common structural features of dermenkephalin and deltorphin. *Life Sci.* 1992; 51:1025–1103. [PubMed: 1326067]
- Misicka A, Lipkowski AW, Horvath R, Davis P, Porreca F, Yamamura HI, Hruby VJ. Structure–activity relationship of biphalin. The synthesis and biological activities of new analogs with modifications in positions 3 and 4. *Life Sci.* 1997; 60:1263–1269. [PubMed: 9096243]
- Misicka A, Lipkowski AW, Stropova D, Yamamura HI, Davis P, Porreca F, Hruby VJ. Identification of the structural elements responsible for high biological activity of dimeric opioid peptide biphalin. In: Shimonishi, Y., editor. *Peptide Science: present and future*. Kluwer Academic Publishers; Dordrecht, The Netherlands: 1999. p. 726-727.
- Mollica A, Davis P, Ma S-W, Lai J, Porreca F, Hruby VJ. Synthesis and biological evaluation of new biphalin analogs with non-hydrazine linkers. *Bioorg Med Chem Lett.* 2005; 15:2471–2475. [PubMed: 15863299]
- Mollica A, Davis P, Ma S-W, Lai J, Porreca F, Hruby VJ. Synthesis and biological activity of the first cyclic biphalin analogs. *Bioorg Med Chem Lett.* 2006; 16:367–372. [PubMed: 16275086]
- Morgan BA, Smith CFC, Waterfield AA, Hughes J, Kosterlitz HW. Structure–activity relations of methionine-enkephalin. *J Pharm Pharmacol.* 1976; 28:660–661. [PubMed: 11324]
- Polt RL, Porreca F, Szabo LZ, Bilsky EJ, Davis P, Abbruscato TJ, Davis TP, Horvath R, Yamamura HI, Hruby VJ. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood–brain barrier. *Proc Natl Acad Sci USA.* 1994; 91:7114–7118. [PubMed: 8041755]
- Schiller PW, Yam CF, Prosmanne J. Synthesis, opiate receptor affinity, and conformational parameters of [4-tryptophan] enkephalin analogs. *J Med Chem.* 1978; 21:1110–1116. [PubMed: 214554]
- Schiller PW, Nguyen TMD, DiMaio J, Lemieux C. Comparison of μ -, δ - and κ -receptor binding sites through pharmacologic evaluation of *p*-nitrophenylalanine analogs of opioid peptides. *Life Sci.* 1983; 33:319–322. [PubMed: 6319885]

- Shimohigashi Y, Costa T, Chen H-C, Rodbard D. Dimeric tetrapeptide enkephalins display extraordinary selectivity for δ opiate receptor. *Nature*. 1982; 297:333–335. [PubMed: 6281658]
- Szekeres PG, Traynor JR. Delta opioid modulation of the binding of guanosine-5'-*O*-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. *J Pharmacol Exp Ther*. 1997; 283:1276–1284. [PubMed: 9400003]
- Toth G, Kramer TH, Knapp R, Lui G, Davis P, Burks TF, Yamamura HI, Hruby VJ. [Cyclic][D-Pen², D-Pen⁵]enkephalin analogs with increased affinity and selectivity for δ -opioid receptors. *J Med Chem*. 1990; 33:249–253. [PubMed: 2153205]
- Yamazaki M, Suzuki T, Narita M, Lipkowski AW. The opioid peptide analogue biphalin induces less physical dependence than morphine. *Life Sci*. 2001; 69:1023–1028. [PubMed: 11508644]

Fig. 1. Structure of biphalin (Bph) and its previously studied 4,4' pF-Phe analogue (pF-Bph) (Misicka et al. 1997). For the sake of clarity, the structure of the non-hydrazine analogues **9a** and **10a** (Mollica et al. 2005) is also illustrated

Scheme 1.

Synthesis of the fluorinated biphalin analogues with non-hydrazine linker **9** and **10**.

Reagents and conditions: **a** EDC·HCl (2.2 eq.), HOBt (2.2 eq.), DIPEA (6.6 eq.), Boc-pF-Phe-OH (2.2 eq.), piperazine (1 eq.) in DMF at r.t. overnight; **b** TFA/CH₂Cl₂ 1:1, r.t. (1.5 h) then EDC·HCl (2.2 eq.), HOBt (2.2 eq.), DIPEA (6.6 eq.), Boc-Gly-OH (2.2 eq.), in DMF at r.t. overnight; **c** TFA/CH₂Cl₂ 1:1, r.t. (1.5 h) then EDC·HCl (2.2 eq.), HOBt (2.2 eq.), DIPEA (6.6 eq.), Boc-D-Ala-OH (2.2 eq.) in DMF at r.t. overnight; **d** TFA/CH₂Cl₂ 1:1, r.t. (1.5 h) then EDC·HCl (2.2 eq.), HOBt (2.2 eq.), DIPEA (6.6 eq.), Boc-Tyr-OH (2.2 eq.) in DMF at r.t. overnight; **e** EDC·HCl (2.2 eq.), HOBt (2.2 eq.), DIPEA (6.6 eq.), Boc-pF-Phe-

OH (2.2 eq.), 1,2-phenylene-diamine (1 eq.) in DMF at r.t. overnight. **f** TFA/CH₂Cl₂ 1:1, r.t. (1.5 h)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1Structures and the physicochemical properties of the biphalin analogues **9–10** and *N*-Boc derivatives **1–8**

No.	Structures	<i>m/z</i> [M + H] ⁺ (ESI)		RP-HPLC ^a , retention time (min)
		Calcd	Found	
1	(Boc-pF-Phe) ₂ -piperazine	617.3151	617.3155	39.50
2	(Boc-pF-Phe) ₂ -1,2-phenylenediamine	639.2994	639.2991	43.79
3	(Boc-Gly-pF-Phe) ₂ -piperazine	731.3580	731.3588	32.91
4	(Boc-Gly-pF-Phe) ₂ -1,2-phenylenediamine	753.3426	753.3425	39.49
5	(Boc-D-Ala-Gly-pF-Phe) ₂ -piperazine	873.4322	873.4318	30.74
6	(Boc-D-Ala-Gly-pF-Phe) ₂ -1,2-phenylenediamine	895.4166	895.4160	37.46
7	(Boc-Tyr-D-Ala-Gly-pF-Phe) ₂ -piperazine	1,199.5589	1,199.5586	29.35
8	(Boc-Tyr-D-Ala-Gly-pF-Phe) ₂ -1,2-phenylenediamine	1,221.5432	1,221.5435	34.15
9	2 TFA-(Tyr-D-Ala-Gly-pF-Phe) ₂ -1,2-phenylenediamine	1,021.4384	1,021.4381	22.73
10	2 TFA-(Tyr-D-Ala-Gly-pF-Phe) ₂ -piperazine	999.4540	999.4542	20.98

^aHPLC column: waters XBridgeTM BEH130 C18, 250 × 4.6 mm, 5.0 μm; HPLC solvent A, 0.1% TFA in water; solvent B, acetonitrile; gradient: 5–95% B in A over 45 min, flow rate 1.0 mL/min, 50 μL injection of a solution containing 1 mg/mL in acetonitrile/water 2:1

Table 2

Binding affinity, GTP binding assay, $E_{\max}$ (%) (net total bound/basal binding $\times$ 100), and in vitro activity

Compound	Binding $K_i^{a,b}$ (nM)		GTP binding ^{b,c} (nM)			Functional bioactivity ^b (nM)		
	K_i^{δ}	K_i^{μ}	EC ₅₀ (nM), hDOR	$E_{\max}$ (%) ^d	EC ₅₀ (nM), hMOR	$E_{\max}$ (%) ^d	MVD	GPI/LMMP
Bph ^e	2.6 $\pm$ 0.4	1.4 $\pm$ 0.2	2.5 $\pm$ 0.5	27 $\pm$ 3	6.0 $\pm$ 0.2	25 $\pm$ 4	27 $\pm$ 1.5	8.8 $\pm$ 0.3
pF-Bph ^f	0.31 $\pm$ 0.1	0.64 $\pm$ 0.3	–g	–g	–g	–g	1.3 $\pm$ 0.1	2.14 $\pm$ 0.6
9a ^h	0.19 $\pm$ 0.04	1.9 $\pm$ 0.2	1.7 $\pm$ 0.2	83 $\pm$ 7	2.5 $\pm$ 0.7	89 $\pm$ 10	0.72 $\pm$ 0.21	40 $\pm$ 13
9	13 $\pm$ 1	0.51 $\pm$ 0.07	0.56 $\pm$ 0.04	72 $\pm$ 6	2.9 $\pm$ 0.5	44 $\pm$ 3	0.66 $\pm$ 0.17	3.7 $\pm$ 1.0
10a ^h	0.65 $\pm$ 0.3	0.48 $\pm$ 0.06	44 $\pm$ 2	56.9 $\pm$ 3	13 $\pm$ 1	47 $\pm$ 5	9.3 $\pm$ 0.4	2.5 $\pm$ 0.7
10	0.09 $\pm$ 0.01	0.11 $\pm$ 0.01	0.80 $\pm$ 0.05	94 $\pm$ 8	1.0 $\pm$ 0.02	77 $\pm$ 8	2.7 $\pm$ 1.7	0.48 $\pm$ 0.07

^aDisplacement of [³H]DAMGO (μ -selective) and [³H]DPDPE (δ -selective) using membrane preparations from transfected cells expressing rat μ -opioid receptor and human δ -opioid receptor, respectively
^b $\pm$ SEM

^cReference compound: [³⁵S]GTP- γ -S

^dNet total bound/basal binding $\times$ 100 $\pm$ SEM

^eData from Lipkowski et al. (1999)

^fData from Misicka et al. (1997)

^gData not present in the original paper

^hRadiolabeled binding and MVD GPI functional bioassays from Mollica et al. (2005)